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Abstract
In this work we analyzed the immune activation properties of different Bifidobacterium strains in order to establish their
ability as inductors of specific effector (Th) or regulatory (Treg) responses. First, we determined the cytokine pattern induced
by 21 Bifidobacterium strains in peripheral blood mononuclear cells (PBMCs). Results showed that four Bifidobacterium
bifidum strains showed the highest production of IL-17 as well as a poor secretion of IFNc and TNFa, suggesting a Th17
profile whereas other Bifidobacterium strains exhibited a Th1-suggestive profile. Given the key role of Th17 subsets in
mucosal defence, strains suggestive of Th17 responses and the putative Th1 Bifidobacterium breve BM12/11 were selected
to stimulate dendritic cells (DC) to further determine their capability to induce the differentiation of naı ¨ve CD4
+
lymphocytes toward different Th or Treg cells. All selected strains were able to induce phenotypic DC maturation, but
showed differences in cytokine stimulation, DC treated with the putative Th17 strains displaying high IL-1b/IL-12 and low IL-
12/IL-10 index, whereas BM12/11-DC exhibited the highest IL-12/IL-10 ratio. Differentiation of naı ¨ve lymphocytes confirmed
Th1 polarization by BM12/11. Unexpectedly, any B. bifidum strain showed significant capability for Th17 generation, and
they were able to generate functional Treg, thus suggesting differences between in vivo and vitro responses. In fact,
activation of memory lymphocytes present in PBMCS with these bacteria, point out the presence in vivo of specific Th17
cells, supporting the plasticity of Treg/Th17 populations and the key role of commensal bacteria in mucosal tolerance and T
cell reprogramming when needed.
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Introduction
Probiotics are live microorganisms that confer beneficial effects
on health when supplied in adequate amounts [1,2]. The genus
Bifidobacterium is one of the most widely used probiotic bacteria,
being predominant in breast fed infants [3–6].
It has been broadly accepted that probiotics, in addition to
their role in the maintenance of the gastrointestinal barrier
function [7–11], exhibit healthy properties through the immu-
nomodulation of both mucosal and systemic immunity under
healthy or pathogenic conditions [12,13]. Gut colonization of
bifidobacteria has been associated with some health-promoting
effects, among which are reduction of certain harmful bacteria,
alleviation or prevention of diarrhea, reduction of lactose
intolerance, attenuation of inflammatory bowel disease symp-
toms, and relief of constipation [11]. Although the mechanisms
underlying these benefits are not completely understood, in
recent years, probiotics have raised interest due to their capability
to regulate the immune response [12,14] through their effects on
intestinal mucosa dendritic cells (DCs). Gut DCs may sample
antigens from food and bacteria of the intestinal lumen [15–17]
and therefore could acquire a mature state and secrete specific
cytokines [18]. In this respect, it has been described that distinct
strains of Bifidobacterium can induce different maturation and
cytokine production patterns on DCs in a strain-specific manner
[18–21]. As a result, the different cytokine profiles released by
DCs may direct the polarization of naı ¨ve CD4
+ T cells towards
different effector or regulatory T cell subsets [22,23]. In fact, it
has been described that different probiotics, such as Lactobacillus
plantarum 299v, Lactobacillus reuteri DSM 12246, and Lactobacillus
johnsonii La1, differ in their ability to induce T cell differentiation
and cytokine production [24–27]. After the first studies, it became
clear that certain probiotic strains cultured in vitro with immune
cells induced IL-12 production, a key cytokine for promoting Th1
responses, characterized by the production of IFNc and TNFa
and essential for a successful defence against intracellular
pathogen infections [28]. On the contrary, other strains induced
high amounts of the anti-inflammatory cytokine IL-10, generat-
ing a Th2 profile. However, the classic Th1/Th2 division was
later changed after the characterization of Th17 cells. This
population produces IL-17, the signature effector cytokine for this
subset, and presents critical functions in host defence against
extracellular bacterial and fungal pathogens, particularly those
encountered at mucosal surfaces [29–36]. Additionally, the gut
immune system has diverse mechanisms of tolerance that avoid
uncontrolled Th1, Th2 or Th17 effector responses to self and
intraluminal antigens. Particularly relevant among them is the
action of CD25
high FOXP3
+ regulatory T cells, which act by
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the thymus (Treg), or may be induced in peripheral organs
(iTreg), including the gut mucosa [38]. Moreover, although there
are few works reporting bacterial iTreg induction, there is
increasing evidence that some probiotic bacteria might induce
FOXP3
+ regulatory T cells from naı ¨ve precursors [27,39–41].
The generation of iTreg cells by probiotics could have a
beneficial effect on allergy and autoimmune diseases, whereas
induction of Th1 or Th17 effector cells would be more interesting
in the defense against pathogens. Consequently, to know the
specific immunomodulatory ability of each strain could allow us
to select specific probiotic bacteria for further biotechnological or
clinical applications in function of the final requirement. Given
the need for appropriate in vitro studies to characterize the
immunomodulatory capacity of different probiotic strains before
their use, in this study, we analyzed the specific immune
activation properties of 21 different Bifidobacterium strains in order
to establish their ability as inductors of effector or regulatory T
cell responses.
Results
Bifidobacterium spp. show different ability to induce
cytokine production by immune cells
Bifidobacterium strains are commensal microorganisms usually
present in the human gut, where they interact with immune cells
[42]. To study the effect that these interactions may have in
modifying cytokine production, we cultured PBMCs isolated from
healthy individuals with 21 different UV-killed Bifidobacterium strains
(bacteria:cell ratio 5:1) and the amount of Th1 (IFNc, TNFa), Th2
(IL-10) and Th17 (IL-17) cytokines was determined in the
supernatants after 4 days of culture by a multiplex immunoassay.
As canbe observed inFigure 1,no relevant cytokine productionwas
detected in unexposed PBMCs (RPMI), whereas LPS (from E. coli)
treatment and the whole set of Bifidobacterium strains tested induced
cytokine production, although clear differences in the levels of IL-
17, IL-10, TNFa and IFNc (p=0.001, p=0.002, p,0.0001 and
p=0.001, respectively; Kendall test) induced by different strains
wereobserved.Specifically,B.bifidumIF10/10,A8,DSM20239and
LMG13195 strainsshowed the highest production of IL-17,existing
significant differences compared with the rest of bifidobacteria
analyzed (p=0.014, T-test). In addition, they induced relatively
poor secretion of IFNc and TNFa, thus suggesting a Th17 profile.
On the contrary, the strains B. animalis subsp. lactis BB-12, B. breve
BM12/11, BM13/14 and B. bifidum KCTC5082 exhibited the
highest capacities for TNFa (p=0.011, T-test) and IFNc produc-
tion (p=0.028, T-test) compared with the other tested bacteria, a
cytokine profile suggestive of a Th1 polarization. Also, B. bifidum
KCTC3357, IF23/2, IF14/5 and B. longum BM18/15 showed the
higher production of IL-10, as well as low levels of Th1 and Th17
cytokines (p=0.036, T-test).
These results indicate that bifidobacteria can stimulate immune
cells to produce different cytokines in a strain-specific manner.
Bifidobacterium spp. induce different T cell polarizing
ability on DCs
The different Th subsets present in PBMCs are the result of the
adaptative immune response to specific antigens, which has been
previously endocyted, processed and presented by DCs to naı ¨ve
CD4
+ T cells. Subsequently, we wanted to determine the capacity
of DCs treated with specific Bifidobacterium strains to differentiate
CD4
+ naı ¨ve T lymphocytes towards different effector Th cells.
Since it has been described that Th17 cells are implicated in the
defence of mucosal barrier against extracellular pathogens, we
found it especially interesting to know the effect of B. bifidum in the
possible induction of this subset. For this purpose, we selected four
Bifidobacterium strains previously found to be suggestive of a Th17
differentiation (B. bifidum LMG13195, L22, A8, IF10/10) and a
probable Th1-inductor strain (B. breve BM12/11) as control.
Monocyte-derived DCs (inmature DC) were exposed to UV-killed
bacteria (bacteria:cell ratio 10:1), or to LPS, and after 48 hours
DC phenotype and cytokine production were evaluated as
indicators of DC maturation. The maturation pattern of DCs
was assessed by flow cytometric analysis of surface marker
expression. All Bifidobacterium strains tested were able to up-
regulate the expression of HLA-DR and the costimulatory
molecules CD80 and CD86, and to down-regulate the production
of CD1a at similar or even higher levels than those observed with
LPS treatment, used as reference for in vitro DC maturation
Figure 1. Cytokine production by human PBMC stimulated with different bifidobacteria strains. PBMCs were cultured with RPMI alone,
or in the presence of LPS (E. coli) or 21 UV-killed bifidobacteria strains at bacteria:cell ratio of 5:1. After four days of culture, supernatants were
collected to quantify the amounts of IL-10, IL-17, IFNc and TNFa by a multiplex assay (Flex set CBA). Histogram shows mean and standard deviation
obtained in four independent experiments performed with different blood donors.
doi:10.1371/journal.pone.0024776.g001
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mature phenotype.
Next, we analyzed the amount of IL-6, IL-8, IL-1b, IL-12p70
and IL-10 present in culture supernatants of bifidobacteria treated
DCs (Figure 2B). All strains induced the production of the
proinflammatory cytokines IL-6 and IL-8 in a similar or lower
level than LPS treatment. In an attempt to predict subsequently
DC-mediated CD4
+ T cell differentiation, we calculated the
cytokine ratios relevant for Th17 (IL-1b/IL-12) and Th1 (IL-12/
IL-10) cell polarization. Thus, B. bifidum LMG13195, L22, A8 and
IF10/10 exhibithigh IL-1b/IL-12andlowIL-12/IL-10index, data
compatible with the cytokine pattern exhibited by PBMCs treated
with these bacteria. Conversely, the highest IL-12/IL-10 ratio was
presented by B. breve BM12/11, in accordance with results from
PBMCs cultures. All these data suggest that different analyzed
bifidobacteria strains are able to generate mature DCs prone to
induce Th17 or Th1 effector lymphocytes.
Then, to confirm this hypothesis, we determined the ability of
Bifidobacterium-DCs to generate specific Th subsets (Th1/Th2/
Th17) from naı ¨ve CD4
+ lymphocytes. To this end, DCs maturated
with LPS or with the selected strains were cocultured with highly
purified allogenic naı ¨ve CD4
+CD45RA
+ T cells at T-cell:DC ratio
of 1:10, and cytokine levels were quantified after 12 days of culture
(Figure 3). All DC-stimulated CD4
+ lymphocytes showed poor
secretion of IL-10 whereas B. breve BM12/11-DCs induced the
highest levels of IFNc and relatively high amounts of TNFa,a s
expected from our previous results. However, although DCs
treated with B. bifidum LMG13195 were the most efficient at
inducing IL-17 production, no significant differences were found
among the strains. These results suggest that the B. bifidum strains
previously selected by their putative Th17 profile were not able to
induce this differentiation from naı ¨ve T cells, at least in our in vitro
conditions, whereas B. breve BM12/11 can efficiently promote the
generation of Th1 responses.
Figure 2. Maturation and cytokine secretion of monocyte-derived DC treated with Bifidobacterium strains. Immature DC were cultured
for 48 h with lipopolysaccharide (LPS) as maturation control, or with different bifidobacterial strains at a bacteria:cell ratio of 10:1. (A) Expression of
CD1a, CD80, CD86 and HLA-DR was analyzed by flow cytometry. Representative profile after 48 hours of culture with LPS or bifidobacteria strain
(B. bifidum L22). Empty histograms belong to immature DCs (discontinuous line), and solid histograms represent specific staining of the indicated cell
surface marker in LPS or Bifidobacterium-stimulated DC. Mean fluorescence intensities (MFI) obtained after subtracting background staining are
provided in each histogram. (B) DC cytokine profile induced by exposure to Bifidobacterium strains. The concentration of IL-8, IL-6, IL-1b, IL-10 and
IL-12 was determined using a multiplex assay. Independent ratios were calculated from each donor. Data are expressed as mean and standard
deviation of four independent experiments performed with different blood donors.
doi:10.1371/journal.pone.0024776.g002
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In view of these inconclusive results, we wanted to determine
the possible effect of these bacterial strains on the induction of
regulatory T cells (Treg). To this end, we analyzed the regulatory
phenotype of the cells obtained after 12 days of stimulation of
purified naı ¨ve CD4
+ lymphocytes (CD45RA
+) with Bifidobacterium-
DCs and determined their ability to suppress the proliferation of
activated effector cells. Although no definitive surface markers for
human Treg have been found, it has been described that only
CD4
+CD45RO
+ cells (memory/effector phenotype) expressing
high levels of CD25 and Foxp3 are able to efficiently suppress
proliferative responses, whereas low/intermediate expression of
these two markers are characteristic of activated cells [43].
Therefore, to analyze the Treg population we quantified, by flow
cytometry, the intracellular expression of FOXP3 and surface
levels of CD127, a marker lost in Treg cells, in CD45RO
+
lymphocytes presenting low and high CD25 levels, according to
the regions shown in Figure 4A. Interestingly, naı ¨ve CD4
+ T cells
stimulated with all Bifidobacterium-DCs presented a higher percent-
age of CD25
high and CD25
low CD45RO
+ cells than lymphocytes
cocultured with LPS-DCs, thus indicating a higher immune
stimulating ability. These figures, however, differed among the
tested strains, B. bifidum 13195-DCs and B. bifidum L22-DCs being
the most efficient up-regulators of CD25 expression. Moreover,
they were the highest inducers of Foxp3 expression, thus
generating a considerable amount of CD25
highFOXP3
highC-
D127
low cells, a phenotype characteristic of Treg cells (Figure 4A).
Finally, we investigated the regulatory function of these putative
Treg lymphocytes by assessing their ability to suppress the
proliferation of effector cells, the typical function of regulatory T
cells. To this end, we determined the capability of these possible
suppressor cells, obtained after stimulation of PBMC with LPS or
Bifidobacterium spp., to inhibit the proliferation of allogenic PBMC
stimulated with PHA (effector cells). Figure 4B shows that cells
stimulated with B. bifidum LMG13195 efficiently suppress the
proliferation of effector cells. This effect was not due to cell death,
since analysis of CD4 and CD25 expression in PHA-stimulated
effector cells co-cultured with B. bifidum treated cells did not cause
a reduction in the amount of CD4
+ lymphocytes compared with
cells treated with LPS (Figure 4C). Moreover, we were able to
observe a significant lower expression of CD25, indicative of a low
activated state of effector cells, in accordance with their reduced
proliferation rate.
Discussion
The interest in the immunomodulatory properties of probiotic
bacteria derives from the observation that intestinal microbiota is
critical for development of the immune system [44]. Since it is
known that different probiotic bacteria present specific immuno-
regulatory effects, it appears reasonable to assume that changing
the microbiota with the use of well-studied probiotics may
influence the immune system in a desired direction.
In the present work we demonstrated great differences between
Bifidobacterium strains in the ability to activate DCs and to drive the
differentiation of naı ¨ve T cells. Firstly, in order to obtain an
approximation in the type of Th cell they could promote, we
analyzed the effect of 21 Bifidobacterium strains, on the induction of
Th1 (IFNc, TNFa), Th2 (IL-10) and Th17 (IL-17) cytokines by
human PBMCs. We found that different bifidobacteria stimulate
immune cells to produce strain-specific cytokines, suggesting that
they could possess different T cell polarizing abilities. Thus, cells
stimulated with strains belonging to B. animalis subsp. lactis (BB-12),
B. breve (BM12/11, BM13/14) and B. bifidum (KCTC5082)
exhibited the highest levels of TNFa and IFNc, representative of
a Th1 response. On the other hand, some B. bifidum stains, such as
IF10/10, A8, DSM20239 and LMG13195, showed a significant
enhancement of IL-17, as well as a poor secretion of IFNc and
TNFa, suggesting a possible Th17 profile.
Immune stimulating activity of the majority of probiotics
commonly added into functional foods is mediated by promoting
Th1 responses. However, Th17 cells are critical to enhance host
protection against extracellular bacteria and fungi, which are not
efficiently cleared by Th1 and Th2 responses [29,31]. Thus, on the
basis of our results, we considered of interest the selection of Th17-
inducer strains for further evaluation of their possible biotechno-
logical use.
Since mature DCs play a key role in T cell function, leading to
proliferation and differentiation towards effector (Th) or regulatory
(Treg) cells, we analyzed the ability of DCs treated with the
possible Th17-inducer B. bifidum strains for the generation of Th17
cells. Accordingly with previous works [19,25,45–47], all Bifido-
bacterium strains tested were able to maturate DCs, however
different patterns of cytokine production were detected. Therefore,
differences in the induction of IL-12, IL-10, and IL-1b by DCs
could be an indicator of the type of Th response that they may
promote. IL-12 is a key immunoregulator cytokine with a central
role in promoting Th1 responses, essential for a successful defence
against intracellular pathogen infections [28]. On the other hand,
the anti-inflammatory cytokine IL-10 exerts an opposite immu-
noregulatory effect, suppressing the production of IL-12 and Th1
cytokines and it may direct CD4
+ T cells towards Th2 cell
differentiation [48]. In addition, recent studies have provided
evidence that IL-1b upregulates the expression of the transcription
factor RORCv2 which can drive human Th17 generation [49–
51]. Our results showed that DCs exposed to the possible Th17-
inducer B. bifidum strains exhibited high IL-1b/IL-12 and low IL-
12/IL-10 proportions, a profile compatible with a Th17 cell
differentiation. Conversely, the highest IL-12/IL-10 ratio was
Figure 3. Cytokine production by CD4
+ T lymphocytes stimulated with Bifidobacterium treated DCs. DCs maturated with LPS, B. bifidum
LMG13195, L22, A8 and IF10/10 or B. breve BM12/11 were cocultured with allogeneic naı ¨ve CD4
+CD45RA
+ T cells at T-cell:DC ratio of 1:10. The
concentration of IL-10, IL-17, IFNc and TNFa was quantified by multiplex assay. Bars represent the mean and standard deviation of four independent
experiments performed with different blood donors.
doi:10.1371/journal.pone.0024776.g003
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the induction of Th1 responses. These results support previous
studies showing that probiotic bacteria influence DC function in a
strain-specific manner [46,52].
Finally, we analyzed the ability of DCs treated with the selected
Th1 and Th17 strains to differentiate naı ¨ve CD4
+ T lymphocytes
into effector or regulatory cells. As expected, B. breve BM12/11-
DCs induced the highest levels of TNFa and IFNc, but,
surprisingly, although B. bifidum LMG13195-DCs upregulated
IL-17 production, no significant differences were found compared
with the other strains, suggesting that they were unable to generate
Th17 cells from naı ¨ve T lymphocytes in these in vitro conditions. In
this regard, it is known that the development of Th17 cells is
closely linked to the generation of iTreg, since both processes share
common cytokine signaling pathways [30,36,53]. Moreover,
several studies revealed the plasticity in the polarization and
balance between Treg and Th17 cell subsets coexisting in the same
tissues [54,55]. Besides, it has been described that FOXP3
+ Treg
cells can secrete IL-17 and express high levels of RORct, as well as
exert suppressor functions [56–58], suggesting that human Th17
cells could originate from Treg subsets. Indeed, Esposito et al [58]
hypothesize that CD4
+FOXP3
+RORct
+ T cells represent a
transient population, able to create both Th17 and Tregs.
In view of these results, we next studied the effect of the selected
strains on the induction of Treg cells. This population is primarily
characterized by the presence of high levels of CD25 and low
expression of CD127. However, the transcription factor FOXP3 is
considered the best functional marker of Tregs, although it is also
transiently expressed in recently activated non-Treg CD4
+
lymphocytes [59,60]. Interestingly, our results showed that DCs
maturated with the bifidobacteria tested presented a higher ability
to activate naı ¨ve T cells than standard LPS-DCs, since they induced
a higher proportion of CD45RO
+CD25
+ cells. However, only DCs
treated with B. bifidum LMG13195 and L22 generated a high
proportion of CD25
highFOXP3
highCD127
low cells. The expression
of FOXP3 was quantified after 12 days in culture, which is far
longer than the transient up-regulation of this molecule observed in
activated effector cells [60,61]. In addition, in vitro functional assays
showed that Treg cells induced by B. bifidum LMG13195 were able
to suppresstheproliferation of effectorcellsmoreefficientlythan the
other strains analyzed. In this regard, Kwon et al recently observed
that administration of the probiotic mixture ITR5 results in an
enhancement of the CD4
+FOXP3
+ Treg population, and suppres-
sion of the progression of murine experimental inflammatory bowel
disease, atopic dermatitis and rheumatoid arthritis [62]. Similarly,
oraladministration ofaprobioticcombinationexerted atherapeutic
Figure 4. Induction of functional Treg cells by Bifidobacterium strains. (A) CD4
+CD45RA
+ T cells were co-cultured with DCs stimulated with
different bifidobacterial strains in a 1:10 ratio. After 12 days of culture determination of Treg cells was assessed by extra/intra-cellular staining by flow
cytometry. Different gates for CD45RO
+ cells with low/intermediate (blue dots) and high (red dots) expression of CD25 were defined, allowing the
quantification of CD25
high FOXP3
highCD127
low lymphocytes. (B) PHA-activated effector cells (allogenic PBMCs) were cultured in the presence of cells
obtained after 7-day stimulation of PBMCs with LPS or Bifidobacterium spp. After 4 days of culture, cells were pulsed with [
3H]thymidine and
incorporation was measured 16 h later. Histogram shows mean and standard deviation of the cpm in stimulated triplicates obtained in 4
independent experiments performed with different blood donors. (C) Analysis of CD4/CD25 expression in the same cultures.
doi:10.1371/journal.pone.0024776.g004
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Treg [63]. However, the possible relationship with IL-17 produc-
tion has not been determined.
The lamina propia of the small intestine contains large numbers
of Th17 and Treg cells [30,36,53], two populations implicated in
antagonistic functions. Tregs have a central homeostatic role in
avoiding autoimmunity and allergy. However, the presence of
mechanisms that rapidly block their suppressive activity and
facilitate immune activation during an acute microbial infection
are necessary. In this situation, diverse cell types secreted
inflammatory cytokines generating a proinflammatory environ-
ment to clear the infection. In this regard, recent studies have
indicated that Treg cells possess the capacity to produce IL-17
when they are activated in the presence of the proinflamatory
cytokines IL-1b and IL-6, presenting sustained FOXP3 expression
and a reversible loss of suppressive function [56,64,65]. Actually,
this Th17/Treg plasticity could explain our apparently discordant
in vitro and ex vivo results. DCs matured in vitro with specific
Bifidobacterium strains polarize naı ¨ve T lymphocytes towards
regulatory FOXP3
+ cells, whereas in ex vivo experiments the same
commensal bacteria induce the production of IL-17, probably due
to the activation of memory Th17 cells present in PBMCs from
healthy individuals. These data support that, in vivo, some
commensal bacteria could maintain mucosal tolerance through
the generation of a Treg pool, but, under danger signals or
inflammatory stimulation, these cells could transdifferentiate to a
Th17 effector subset, relevant in the defense against extracellular
pathogens. In fact, a key role has been reported for commensal
microbiota in the development of both Th17 and Treg cells
[32,66,67].
In summary, the present work demonstrates great differences
between Bifidobacterium strains in their ability to activate DCs and
to drive the differentiation of naı ¨ve T cells. Our results support the
fact that specific food and commensal bacteria may play a role in
balancing the development of Treg and Th17 cell compartments
in the intestine through the existence of Treg cells with plasticity to
show an effector function, secreting IL-17, or a regulatory action,
suppressing activation of the immune system, depending on the
environment and the nature of the stimuli [32]. For instance,
colonization of the gut by bacteria able to favour a Treg
polarization, such as B. bifidum LMG13195, represents an
attractive goal in the prevention and treatment of inflammatory
diseases characterized by an overreaction of the immune system,
such as autoimmune diseases, asthma and allergy. Moreover, since
Treg cells may be capable of IL-17 secretion under certain
conditions, adaptive immune responses against mucosal extracel-
lular pathogens cannot be impaired.
Materials and Methods
Ethics statement
Ethics approval for this study was obtained from the Bioethics
Committee of CSIC (Consejo Superior de Investigaciones Cientı ´ficas) and
from the Regional Ethics Committee for Clinical Research (Servicio
de Salud del Principado de Asturias). All determinations were
performed with fully informed written consent from all partici-
pants involved in the study.
Bacterial strains and culture conditions
The different bacterial strains used in this study are shown in
Table 1. All cultures were incubated at 37uC in anaerobic
conditions (10% H2, 10% CO2 and 80% N2) in a chamber Mac
500 (Don Whitley Scientific, West Yorkshire, UK). For stimulation
of immune cell experiments, overnight bacterial cultures were used
to inoculate (1%) 150 ml of IMDM broth (Sigma Chemical Co, St.
Louis, MO, USA, reference number I6529) supplemented with the
following compounds: 16.5 mM cysteine, 74.0 mM adenine,
89.2 mM uracil, 65.7 mM xanthine, 66.2 mM guanine, 2.47 mM
ammonium citrate tribasic, 12.19 mM sodium acetate, 166 mM
MnSO4NH2O, 17.4 mM ZnSO4N7H 2O, 10.5 mM CoCl2N6H 2O,
0.4 mM CuSO4N5H 2O, 25.2 mM FeCl2N4H 2O, 22.2 mM
fructose, 22.2 mM glucose, 0.2% of Tween 80 and 1% of the
permeates resulting from the dialysis (2 kDa cut-off membrane) of
10 times concentrated MRS broth (Difco Laboratories, Detroit,
MI, USA) dialyzed against 10 volumes of milli-Q water. After
incubation, cultures were harvested by centrifugation, bacterial
pellets were washed three times in PBS buffer (Oxoid Limited,
Hampshire, UK) and resuspended in 5 ml of the same buffer.
Bacterial levels in the cell suspensions were determined by plate
counting and cultures were killed by exposing them to UV light in
a UV chamber (15 W, Selecta, Barcelona, Spain) for 90 min. Plate
counting was carried out after UV treatment to corroborate the
absence of bacteria able to recover in the proper medium. UV
treated bacterial suspensions were then distributed in single use
aliquots, frozen in liquid N2 and stored at 280uC until use.
Isolation of PBMCs
Human peripheral blood mononuclear cells (PBMCs) were
obtained from standard buffy-coat preparations from routine
blood donors (Asturian Blood Transfusion Center, Oviedo, Spain)
by centrifugation over Ficoll-Hypaque gradients (Lymphoprep,
Nycomed, Oslo, Norway). All blood donors (the number is
specified in each figure legend) were healthy adult volunteers
without any pathology or treatment.
PBMCs stimulation with Bifidobacterium strains
2610
4 PBMCs were incubated with bacteria at PBMCs:bac-
teria ratio of 1:5. All cultures were performed in triplicate wells in
200 ml of complete RPMI medium (RPMI 1640 containing 2 mM
L-glutamine and 25 mM Hepes, Bio Whitaker, Verviers, Belgium,
supplemented with 10% heat-inactivated fetal calf serum and the
antibiotics streptomycin and ampicillin at 100 mg/ml) at 37uC and
5% carbon dioxide. After 4 days of culture, 100 ml of supernatants
from these cultures were collected for cytokine quantification.
Generation of Monocyte-derived DCs
Monocytes were isolated from previously obtained PBMCs by
negative selection using the Human Monocyte enrichment kit,
according to the protocol provided by EasySep, StemCell
Technologies (Canada). Purified monocytes were .95% CD14
+.
Immature DCs were obtained from isolated monocytes by
standard procedures. Thus, monocytes were cultured in 24-well
plates at a concentration of 5610
5 cells/ml for 7 days at 37uC and
5% carbon dioxide in complete RPMI medium in the presence of
recombinant human (rh) IL-4 (35 ng/ml) and rhGM-CSF (70 ng/
ml) (R&D Systems, Abingdon, UK). At days 2 and 5, 0.5 ml of the
medium was removed without disturbing the clusters of developing
DC and 0.5 ml of freshly made GM-CSF- and IL-4-containing
medium was added to the wells, restoring the final volume in each
well to 1 ml. At day 7, immature DCs were recovered, washed and
resuspended in complete RPMI medium at 5610
5 cells/ml for
subsequent maturation.
Stimulation of monocyte-derived DCs with bifidobacteria
To examine the effects of bifidobacteria on DC maturation,
different Bifidobacterium strains, killed by UV radiation, were added
to immature DCs at a DC:bacteria ratio of 1:10 in complete RPMI
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coli 0111:B4 (Sigma), as a positive control of maturation. After
48 hours, supernatants from these cultures were collected, clarified
by centrifugation and stored at220uC forcytokineanalysis whereas
DCs were harvested for phenotypic characterization.
Flow cytometric analysis
Phenotypic studies of DCs, T lymphocytes and PBMCs were
performed after staining with the appropriate monoclonal
antibody (mAb) using a FACSCanto II flow cytometer (Becton
Dickinson, BD Biosciences, San Diego, CA). DCs were stained
with anti-CD86 fluorescein isothiocyanate (FITC), CD80 phyco-
erythrin (PE), HLA-DR (PE-Cy5) mAb, anti- CD1a-FITC mAb,
or with the corresponding isotype matched conjugated irrelevant
mAb as a negative control. All mAb were supplied by Becton
Dickinson Pharmingen. Staining was performed for 30 min at
4uC, and cells were washed twice in staining buffer and
resuspended in PBS. To determine Treg phenotype, cultured
CD4+ lymphocytes were first extracellularly stained with
CD45RO-APC, CD25-FICT and CD127 PE-Cy7 (eBiosciences,
San Diego, CA). Then, cells were fixed, permeabilized and
intracellularly stained with anti-FOXP3 PE (clone PCH101)
following the manufacturer’s instructions (eBiosciences). Isotype
controls were used to set up quadrants and CD4
+CD25
+ T cells
were subdivided into CD25
low and CD25
high populations. A
minimum of 10,000 cells were acquired and analyzed using the
FACSDiva Software 6.1.2 (BD Biosciences). The specific fluores-
cence intensity was quantified as the mean fluorescence intensity
(MFI) calculated by subtracting the background of isotype-
matched control staining from the total fluorescence.
Naı ¨ve CD4+ T cell stimulation with Bifidobacterium-DCs
CD4+ T cells were isolated from PBMCs by negative selection
using the Human CD4+ T Cell Enrichment Kit (EasySep, Stem
Cell Technologies Inc.), following manufacturer’s instructions, and
then naı ¨ve CD45RA
+ T cells were separated after depletion of
CD45RO+ cells (Miltenyi Biotec GmbH, Bergisch Gladbach,
Germany). Monocyte-derived DCs maturated after 48 h treat-
ment with LPS or with B. bifidum LMG13195, L22, A8, IF10/10
or B. breve BM12/11 (Bifidobacterium-DCs) were cocultured with
purified allogeneic CD4
+CD45RA
+ T cells in 48-well plates at
DC:T-cell ratio of 1:10. At day 5 and 8, cells incubated with all
treatments were expanded with IL-2 (30 U). After 12 days, culture
supernatants were collected for cytokine measurements, and cells
were used to analyze the Treg phenotype by flow cytometry.
Suppression assays
The suppressive function of Bifidobacterium-stimulated PBMCs
was assessed by determining their ability to inhibit effector cell
proliferation by quantifying [
3H]thymidine incorporation in
cultured cells. To this end, 10
5 PBMCs stimulated with LPS or
different Bifidobacterium strains were cultured with PBMCs
activated with 2 mg/ml PHA (effector cells) at ratio 1:1. All
cultures were performed in triplicate wells in 200 mL of complete
medium in 96-well round-bottom microtiter plates (Costar,
Cambridge, MA). At day 4 of culture, 1 mCi/well [
3H]thymidine
was added to the cultures. After 16 h cells were harvested onto
glass fiber filters for counting cell-incorporated [
3H]thymidine
using standard scintillation techniques (Packard Instruments,
Downers Grove, IL). Results were determined as the mean counts
per minute (cpm) values measured in stimulated triplicates.
Table 1. Bacterial strains, origin and relevant phenotype.
Strain Origin Relevant characteristics Selected reference
B. animalis subsp. lactis BB-12 Intestine of adult Known probiotic strain [68]
B. longum BM 18/6 (IPLA 20002) Breast milk - [6]
B. longum IF 18/6 (IPLA 20023) Infant feces - This work
B. longum BM 6/2 (IPLA 20001) Breast milk - [6]
B. longum BM 18/15 (IPLA 20003) Breast milk Resistant to bile [6]
B. longum IF 14/6 (IPLA 20011) Infant feces - This work
B. bifidum IF 10/10 (IPLA 20015) Infant feces - [19]
B. bifidum A8 Dairy product Mucin-degrading strain [69]
B. bifidum DSM20239 Adult Mucin-degrading strain [70]
B. bifidum LMG13195 Infant, intestine - [71]
B. bifidum L22 Adult Mucin-degrading strain [70]
B. bifidum KCTC3357 Human feces - -
B. bifidum IF 23/2 (IPLA 20017) Infant feces - This work
B. bifidum IF 14/5 (IPLA 20024) Infant feces - This work
B. bifidum IF 13/11 (IPLA 20016) Infant feces - This work
B. bifidum KCTC5082 - - -
B. bifidum JCM7003 Human feces - -
B. breve LMG13208 Infant In vitro antimutagenic activity [72]
B. breve BM 13/14 (IPLA 20005) Breast milk - [6]
B. breve BM 12/11 (IPLA 20004) Breast milk - [6]
B. breve BM 23/20 (IPLA 20006) Breast milk Tolerant to gastric juice [6]
DSM, German Collection of Microorganisms and Cell Cultures; LMG/BCCM, Belgian Co-ordinated Collections of Microorganims; KCTC, Korean Collection for Type
Cultures; JCM, Japan Collection of Microorganisms.
doi:10.1371/journal.pone.0024776.t001
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Cytokine levels in cell culture supernatants were quantified by a
multiplex immunoassay (cytometric bead array, CBA, BD) using
FacsCantoII flow cytometer (BD). To determine cytokine
production of stimulated DCs the Human Inflammation kit for
CBA was used (IL-8, IL-6, IL-1b, IL-10, TNFa and IL-12p70)
whereas quantification of cytokine production by cultured CD4+
T lymphocytes and PBMCs was performed using a Flex Set for
CBA including IL-17, IL-10, TNFa and IFNc. Briefly, microbeads
with distinct fluorescence intensities, coated with captured
antibody specific for each cytokine, were incubated with serum
samples and PE-conjugated detection antibodies for 2 hours. The
samples were then washed, resuspended in 300 ml wash buffer,
and analyzed using FCAP array software (BD Biosciences). The
detection limits were: IL-8: 3.6 pg/ml; IL-1b: 7.2 pg/ml; IL-6:
2.5 pg/ml; IL-10: 3.3 pg/ml; TNFa: 3.7 pg/ml and IL-12p70:
1.9 pg/ml for the Human Inflammation kit and IL-17: 0.3 pg/ml;
IL-10: 0.13 pg/ml; TNFa: 0.7 pg/ml and IFNc: 0.8 pg/ml for the
Flex Set.
Statistical analysis
The Kolmogorov–Smirnov test was used to assess the normal
distribution of the data. Cytokine levels were normally distributed
and then differences between cell treatments were evaluated by the
parametric T-test. Due to the existence of genetically determined
differences between individuals in cytokine production, Kendall W
tests for related samples were used. Results were represented by
mean 6 standard deviation. The SPSS 18.0 statistical software
package (SPSS Inc., Chicago, IL) was used for all determinations
and a value of p,0.05 was considered significant.
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